NEW YORK, NY / ACCESSWIRE / August 25, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Oatly Group AB (NASDAQ:OTLY)
Class Period: May 20, 2021 - July 15, 2021
Lead Plaintiff Deadline: September 24, 2021
The OTLY lawsuit alleges that throughout the class period, Oatly Group AB made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.
Learn about your recoverable losses in OTLY: https://www.kleinstocklaw.com/pslra-1/oatly-group-ab-loss-submission-form?id=18948&from=1
Ardelyx, Inc. (NASDAQ:ARDX)
Class Period: August 6, 2020 - July 19, 2021
Lead Plaintiff Deadline: September 28, 2021
The complaint alleges that throughout the class period Ardelyx, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
Learn about your recoverable losses in ARDX: https://www.kleinstocklaw.com/pslra-1/ardelyx-inc-loss-submission-form?id=18948&from=1
Iterum Therapeutics Plc (NASDAQ:ITRM)
Class Period: November 30, 2020 - July 23, 2021
Lead Plaintiff Deadline: October 4, 2021
The complaint alleges that during the class period Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in ITRM: https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=18948&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/661368/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-OTLY-ARDX-and-ITRM
